TY - JOUR
T1 - Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States
AU - Venkitachalam, Lakshmi
AU - McGuire, Darren K
AU - Gosch, Kensey
AU - Lipska, Kasia
AU - Inzucchi, Silvio E.
AU - Lind, Marcus
AU - Goyal, Abhinav
AU - Spertus, John A.
AU - Masoudi, Frederick A.
AU - Jones, Philip G.
AU - Kosiborod, Mikhail
N1 - Funding Information:
Darren McGuire has a consultancy relationship with F. Hoffmann LaRoche, Daiichi-Sankyo, Genentech, Sanofi-Aventis, Novo-Nordisk, and Tethys Bioscience. Silvio Inzucchi received research grant support from Lilly, received honoraria from Novo-Nordisk, and is a consultant for Medtronic. Mikhail Kosiborod is a consultant for Medtronic Minimed, Gilead Sciences, Genentech, Hoffman La Roche, and Boehringer-Ingleheim and received research grants from Medtronic Minimed, Glumetrics, Gilead Sciences, Genentech, and Sanofi-Aventis. Lakshmi Venkitachalam, Kensey Gosch, Kasia Lipska, Abhinav Goyal, Fredrick Masoudi, Philip Jones, and John A. Spertus have nothing to disclose.
Funding Information:
The research for this article was supported by the American Heart Association Career Development Award in Implementation Research awarded to Dr Kosiborod. Dr Venkitachalam was supported by the American Heart Association Pharmaceutical Roundtable–David and Stevie Spina Outcomes Research Postdoctoral Fellowship.
Funding Information:
Details about the Cerner HealthFacts database have been previously described. 7,20-23 Briefly, deidentified information on consecutive patients treated between January 1, 2000, and December 31, 2008, was collected from participating hospitals. Rigorous quality assurance efforts and audits were conducted on a regular basis to ensure data accuracy. Data collected included patient demographics, comprehensive pharmacy, and laboratory data (including all venous and finger-stick BG measurements during hospitalization), inhospital procedures (including cardiac catheterization, coronary artery bypass surgery, and percutaneous coronary intervention), medical history and comorbidities (determined from International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnostic codes), and hospital characteristics. A total of 78 hospitals contributed data to the Health Facts database; the median number of patients from each site was 219 (interquartile range [IQR] 48-1,030), and the median duration of hospitals' participation was 2.9 years (IQR 1.2-5.3 years). These hospitals were comparable in their characteristics with those reported in other national registries 24 : they were mostly urban (88.5%), were less frequently teaching (35.9%) hospitals, and represented all geographic regions of the United States (Northeast 38.5%, Midwest 25.6%, South 26.9%, and West 9%) and a broad range of sizes (bed size 1-99, 26.9%; 100-199, 20.5%; 200-299, 23.1%; 300-499, 17.9%; and ≥500 beds, 11.5%). All data were deidentified before they were provided to the investigators; accordingly, an exemption from review was granted by the Saint Luke's Hospital Institutional Review Board. Funding for research was provided by the American Heart Association Career Development Award in Implementation Research awarded to Dr Kosiborod. Dr Venkitachalam was supported by the American Heart Association Pharmaceutical Roundtable–David and Stevie Spina Outcomes Research Postdoctoral Fellowship. The Cerner Corporation provided the data but had no role in study funding, design, analyses, manuscript drafting, or review of the manuscript. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
PY - 2013/8
Y1 - 2013/8
N2 - Background Elevated blood glucose is associated with higher mortality in patients with acute myocardial infarction (AMI). Although clinical guidelines recommend targeted glucose control in this group, clinical trials have yielded inconclusive results. Our objective was to understand how this lack of evidence impacts the management of severe hyperglycemia in routine practice. Methods We examined insulin use among 4,297 AMI admissions with a mean hospitalization blood glucose of ≥200 mg/dL across 55 US hospitals from 2000 to 2008. Temporal trends and interhospital variation in 2 measures of insulin use during hospitalization - any (subcutaneous, intravenous [IV], short acting, long acting) and IV insulin - were examined using hierarchical Poisson regression models. Results Of the 4,297 admissions, 2,618 (61%) received any insulin and 538 (13%) received IV insulin. After multivariable adjustment, a slight increase in insulin use was observed per admission year (relative risk [RR] 1.06, 95% CI 1.01-1.11). There was a modest (albeit nonsignificant) increase in IV insulin use seen before May 2004 (RR 1.18, 95% CI 0.96-1.47), with no significant change thereafter (RR 0.99, 95% CI 0.92-1.09). Marked variability in insulin use was observed across hospitals (median rate ratio 1.5 [any insulin] and 1.8 [IV insulin]), which did not change over time. Conclusions Insulin use among patients with AMI and severe hyperglycemia has remained low over the past decade, with substantial and persistent interhospital variation. These observations reflect marked clinical uncertainty with regard to glucose management in AMI, underscoring the imperative for a definitive clinical trial in this field.
AB - Background Elevated blood glucose is associated with higher mortality in patients with acute myocardial infarction (AMI). Although clinical guidelines recommend targeted glucose control in this group, clinical trials have yielded inconclusive results. Our objective was to understand how this lack of evidence impacts the management of severe hyperglycemia in routine practice. Methods We examined insulin use among 4,297 AMI admissions with a mean hospitalization blood glucose of ≥200 mg/dL across 55 US hospitals from 2000 to 2008. Temporal trends and interhospital variation in 2 measures of insulin use during hospitalization - any (subcutaneous, intravenous [IV], short acting, long acting) and IV insulin - were examined using hierarchical Poisson regression models. Results Of the 4,297 admissions, 2,618 (61%) received any insulin and 538 (13%) received IV insulin. After multivariable adjustment, a slight increase in insulin use was observed per admission year (relative risk [RR] 1.06, 95% CI 1.01-1.11). There was a modest (albeit nonsignificant) increase in IV insulin use seen before May 2004 (RR 1.18, 95% CI 0.96-1.47), with no significant change thereafter (RR 0.99, 95% CI 0.92-1.09). Marked variability in insulin use was observed across hospitals (median rate ratio 1.5 [any insulin] and 1.8 [IV insulin]), which did not change over time. Conclusions Insulin use among patients with AMI and severe hyperglycemia has remained low over the past decade, with substantial and persistent interhospital variation. These observations reflect marked clinical uncertainty with regard to glucose management in AMI, underscoring the imperative for a definitive clinical trial in this field.
UR - http://www.scopus.com/inward/record.url?scp=84880924102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880924102&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2013.05.012
DO - 10.1016/j.ahj.2013.05.012
M3 - Article
C2 - 23895815
AN - SCOPUS:84880924102
SN - 0002-8703
VL - 166
SP - 315-324.e1
JO - American heart journal
JF - American heart journal
IS - 2
ER -